Advertisement
Singapore markets open in 5 hours 8 minutes

  • Straits Times Index

    3,323.38
    +0.18 (+0.01%)
     

  • S&P 500

    5,229.57
    -37.38 (-0.71%)
     

  • Dow

    38,051.94
    -389.60 (-1.01%)
     

  • Nasdaq

    16,722.87
    -197.71 (-1.17%)
     

  • Bitcoin USD

    68,464.59
    +1,142.45 (+1.70%)
     

  • CMC Crypto 200

    1,443.27
    -12.60 (-0.86%)
     

  • FTSE 100

    8,231.05
    +47.98 (+0.59%)
     

  • Gold

    2,363.00
    -1.10 (-0.05%)
     

  • Crude Oil

    77.88
    -1.35 (-1.70%)
     

  • 10-Yr Bond

    4.5540
    -0.0700 (-1.51%)
     

  • Nikkei

    38,054.13
    -502.74 (-1.30%)
     

  • Hang Seng

    18,230.19
    -246.82 (-1.34%)
     

  • FTSE Bursa Malaysia

    1,604.26
    -1.09 (-0.07%)
     

  • Jakarta Composite Index

    7,034.14
    -7,140.23 (-50.37%)
     

  • PSE Index

    6,371.75
    -39.66 (-0.62%)
     

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Revolution Medicines, Inc.
·1-min read
Revolution Medicines, Inc.
Revolution Medicines, Inc.

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

CONTACT: Revolution Medicines Media & Investor Contact: Erin Graves 650-779-0136 egraves@revmed.com